


Science Commons

International Seminar
Open Access for Developing Countries
21 September 2005
Salvador, Brazil





Science Commons

- A project of Creative Commons
- Broader focus:
 - Copyrights and open access
 - Patents and licensing
 - Data and databases
- Multidisciplinary, but current focus on biomedical sciences

Advisory Board



- **Paul David**
Professor of Economics, Stanford University / Oxford University
Director, Knowledge Networks and Institutions for Innovation Program
- **Michael Eisen**
Principal Investigator, Life Sciences Division, Lawrence Berkeley National Lab
Founder, Public Library of Science
- **Joshua Lederberg**
1958 Nobel Prize Winner, Physiology or Medicine
Foundational Geneticist
- **Arti Rai**
Professor of Law at Duke Law School
Leading thinker on patents, open source discovery models and institutional designs for licensing
- **Sir John Sulston**
2002 Nobel Prize Winner, Physiology or Medicine
Sequenced *c. elegans* genome, led UK efforts in the Human Genome Project



Openness As A Default Rule



sc-publishing



sc-licensing

Protein Databases

[Domains](#)
[Proteins](#)

[PROW](#)
[RefSeq](#)

Structure Databases

[Domains](#)
[3D Domains](#)

[Structure \(MMDB\)](#)

Taxonomy Databases

[Taxonomy](#)

Genome Databases

[Cancer Chromosomes](#)
[COGs](#)
[Gene](#)

[Genome Project](#)
[Genomes](#)


Expression Databases

[GEO](#)
[GEO Datasets](#)

[SAGE](#)

sc-data

Scholarly Publishing: Ecosystem



Graph by Robert Terry,
Wellcome Trust

Wanted: social entrepreneurs

Scientists-turned-entrepreneurs are resuscitating the research and development of drugs for neglected diseases. Researchers, administrators and funders should contribute their expertise to help these initiatives — or set up their own.

The all-embracing open-source encyclopedia Wikipedia doesn't have a dedicated page on kala-azar, or visceral leishmaniasis. But who cares? After all, the disease only transforms vast numbers of people in developing countries into walking skeletons carrying bellies bloated by an enlarging liver and spleen. With drugs costing up to US\$200 a course, it often goes untreated, causing some 200,000 deaths each year. In the research and development (R&D) chains that lead to drugs, more attention is devoted to silicone breast implants and pills for erectile dysfunction than to the roughly 8,000 orphan diseases. These neglected diseases each touch up to just 2,000 people, but together they affect millions.

The root cause is that the markets for these diseases are too small to seriously interest the large pharmaceutical companies, which are involved in partnerships to address them but must also answer to their shareholders. What can be done to redress this balance by the many stakeholders along the route from research to product?

A round table on neglected diseases, co-organized by *Nature* at the BioVision World Life Sciences Forum in Lyon, France, last week, left a depressing sense of how far we have all got to go to seriously address neglected diseases — but also provided some encouraging sparks of enlightenment, and pointers to possible ways forward.

The meeting was held to celebrate the 50th anniversary of the approval of a polio vaccine. Polio is on the brink of being eradicated, something that would have been impossible without the March of Dimes, which courageously supported key basic research into the disease, and the Rotary Foundation, which got the vaccine into the field by raising more than \$500 million and providing volunteers. They addressed critical bottlenecks, and won. As a result, most people reading this will be unaware that just a few decades ago, polio was a disease that every parent feared.

New leaders

A new generation of 'social entrepreneurs' are testing imaginative ways to tackle neglected diseases. One small step for Victoria Hale, for example, may be a giant leap for mankind: the founding of a San Francisco-based not-for-profit drug company, the Institute for

Neglected Diseases Initiative, instigated by Doctors without Borders, for a host of other neglected diseases. As well as testing and reformulating existing drugs, such initiatives are bridging the abyss between research and clinical development by focusing on leads that would otherwise have remained in the lab for lack of an industry sponsor.

Another key bottleneck in the pipeline is preclinical research in animal models or cell cultures. Genomics has revealed the molecular basis of some 1,200 orphan diseases, as well as major ones such as malaria and tuberculosis, revealing new drug targets. This is opening up many orphan diseases to possible cures for the first time. If the molecular basis involves the expression of interleukin A, for example, then existing interleukin A inhibitors might make potential drugs. But the many drug analogues needed by academic researchers to test this plethora of emerging targets are found only in industry.

So French gene therapist and social entrepreneur Alain Fischer is trying to persuade companies to give researchers access to the wealth of relevant drugs they hold but have not developed. The fledgling European Rare Disease Therapeutic Initiative gives the company the right of first refusal to market a promising molecule for a neglected disease. If it declines, the researchers can take it to another company or funder to take it to the clinic.

Persistence for change

The catch is that all these initiatives are relatively small. Funding is a big issue, but Hale is bullish. The money is out there, she says, provided that scientists, doctors and social entrepreneurs build awareness and argue their case. Robert Scott, who spearheads the Rotary campaign against polio, agrees, pointing out that governments, companies and research institutes change: someone who says 'no' today may say 'yes' tomorrow. Dogged persistence pays off.

Ironically, getting rights and molecules from universities is often harder than obtaining them from companies. University technology offices tend to patent aggressively, look no further than generating income, and often fail to include provisions beneficial to tackling orphan diseases in their licensing deals with companies. More scientists and their institutions should sign up to organizations such as





USERNAME
wilbankscrea
Save passwor
login to n

Search journal

▸ [Advanced search](#)

MY ACCOUNT

E-

[Journal home](#) > [Subscribe now!](#)

Journal home

Advance online publication

Current issue

Archive

Supplements

Web focuses

About the journal

For authors and referees

 Online submission

Reprints and Permissions

Gateways

Asia gateway

ACCESS

Most users gain access to full text articles through a site license. This is available to institutional customers only. For further information visit the [Librarian Gateway](#).

Full-text articles are also available through a number of other options:

I want to purchase this article

Select this option to view this article immediately and access it for seven days.

Price: US\$30*

In order to purchase this article you must be a registered user. [Click here to register](#) or log in above.

I want to subscribe to *Nature*

Select this option to purchase a personal subscription.

Subscribe now

Impact on Developing Nations



- Keynote address, International Conference on Open Access, June 2005:
 - “The persistent and sharp elevation in price of academic periodicals seriously restricts the acquisition of scientific information”
 - “The resources formed from public investment become the proprietary property of publishers and *are then sold back to the developing countries at a high price*”
 - Qiheng Hu, Vice Chair of Chinese Association for Science and Technology



Reaction: Open Access

- Open-access (OA) literature
 - Digital
 - Online
 - Free of charge
 - Free of most copyright and licensing restrictions
- OA removes *price* barriers and *permission* barriers
- OA should apply to the full-text, not just to abstracts or summaries

CC Licenses: OA Journals



PLoS PUBLIC LIBRARY of SCIENCE

Home About PLoS PLoS Journals Support PLoS FAQ News Contact Jobs @ PLoS Search

License

 **PLEASE CLICK HERE TO READ THE FULL LEGAL CODE OF THE LICENSE.**

PLoS has chosen to apply the **Creative Commons Attribution License** to all works we publish (**click here to read the full-text legal code**). This broad license was developed to facilitate open access to, and free use of, original works of all types, and has been adopted by a growing group of authors and artists. Applying this standard license to your work will provide strong legal protection to you and those wishing to use your work, and thus ensure your right to make your work freely and openly available. Authors will retain copyright of the work.

Please direct your questions and comments to license@plos.org.

(This license replaces the **previously posted versions** of the open-access license - **Version 1.0b** and **Version 1.0** - as of April 22, 2003.)



CC Licenses - OA Repositories



文献俱乐部

- [KITP Online Conferences, Lectures and Seminars](#)
- [Journal Club for Condensed Matter Physics](#)
- [Nanoscale Physics Journal Club](#)
- [BIOPHYSICS JOURNAL CLUB](#)
- [中国科学院理论物理研究所 / 交叉中心](#)

研究者主页

- ['t Hooft, Gerard](#)
- [Leo P. Kadanoff](#)
- [Edward Witten](#)
- [Anthony J. Leggett](#)
- [Robert B. Laughlin](#)

Google 提供的广告

查看相关广告：

特别声明：奇迹文库不是任何形式的“出版物”，也不是“网络杂志”，奇迹文库不存在任何形式的审稿机制。用户向奇迹文库提交文章成功，并不代表我们支持其观点或行为。我们尊重每一位作者的文章和思想，除内容不完整，重复提交的文章外，原则上我们不拒绝大数提交的任何文章。如果你不同意作者的观点，请在奇迹文库发表你的评论或反驳文章。投稿邮箱：ianwest@163.com

京ICP备05003605号 Copyright 2004: [创作共用协议 \(Creative Commons\)](#) | [关于我们](#) | [利用互联网开放共享科研论文倡议书](#) | [意见建](#)



Bethesda Statement on OA

- The author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, **and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works**, in any digital medium for any responsible purpose, subject to proper attribution of authorship[2], as well as the right to make small numbers of printed copies for their personal use.



Attribution 2.5

You are free:

- to copy, distribute, display, and perform the work
- to make derivative works
- to make commercial use of the work

Under the following conditions:



Attribution. You must attribute the work in the manner specified by the author or licensor.


- For any reuse or distribution, you must make clear to others the license terms of this work.
- Any of these conditions can be waived if you get permission from the copyright holder.

Your fair use and other rights are in no way affected by the above.

This is a human-readable summary of the [Legal Code \(the full license\)](#).



Creative Commons





Answer three simple questions to choose a license.

Choose License

With a Creative Commons license, you keep your copyright but allow people to [copy and distribute your work](#) provided they [give you credit](#) -- and only on the conditions you specify here. If you want to offer your work with no conditions, choose the [public domain](#).

Allow commercial uses of your work? ([more info](#) )

- Yes
- No

Allow modifications of your work? ([more info](#) )

- Yes
- Yes, as long as others share alike ([more info](#) )
- No

Jurisdiction of your license ([more info](#) )

Generic 

Tell us the format of your work:

Other 

[Click to include more information about your work.](#)

Select a License



In total, the license is a three Layer Interface:



This work is licensed under a [Creative Commons License](#).

Human-Readable Commons Deed

The image shows a thumbnail of the Creative Commons Commons Deed. It features the CC logo and the text 'creative commons COMMONS DEED'. Below this, it lists the Attribution-NonCommercial-ShareAlike 4.0 license. The document explains that users can copy, distribute, display, and perform the work, and make derivative works, provided they give credit to the original author, do not use the work for commercial purposes, and share any new creations under the same license.

Lawyer-Readable Legal Code

The image shows a thumbnail of the Creative Commons Legal Code. It features the CC logo and the text 'creative commons LEGAL CODE'. The document provides a detailed legal interpretation of the license terms, including definitions of 'Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License', 'Work', 'Derivative Work', and 'Commercial Purpose'. It also outlines the conditions for using the work and the requirements for creating and distributing derivative works.

Machine-Readable Digital Code

The image shows a thumbnail of the Creative Commons Digital Code. It features the CC logo and the text 'creative commons DIGITAL CODE'. This document is a machine-readable version of the license, using a structured format to define the license terms and conditions. It includes metadata such as the license name, version, and the URL of the license text.



Then, you'll get a logo to put on your web page.

49. Thompson MA, Ransom DG, Pratt SJ, MacLennan H, Kieran MW (1998) The cloche and spadetail genes differentially affect hematopoiesis and vasculogenesis. *Dev Biol* 197: 248–269. [Find this article online](#)
50. Kim HJ, Bar-Sagi D (2004) Modulation of signalling by *Sprouty* A developing story. *Nat Rev Mol Cell Biol* 5: 441–450. [Find this article online](#)
51. Brekken RA, Sage EH (2001) SPARC, a matricellular protein: At the crossroads of cell-matrix communication. *Matrix Biol* 19: 816–827. [Find this article online](#)
52. Marin F, Charnay P (2000) Hindbrain patterning: FGFs regulate *Krox20* and *mafB/kr* expression in the otic/preotic region. *Development* 127: 4925–4935. [Find this article online](#)



PLoS Biology is an open-access journal published by the nonprofit organization [Public Library of Science](#).



All journal content, except where otherwise noted, is licensed under a [Creative Commons Attribution License](#).





Creative Commons Worldwide

We are excited to announce the International Commons -- an offshoot of our licensing project dedicated to the drafting and eventual adoption of jurisdiction-specific licenses. The International Commons is being lead by [Christiane Asschenfeldt \(email\)](#), with help from member jurisdictions.

Completed Licenses

We have completed the process and developed licenses for the following jurisdictions:



[Australia](#)



[Austria](#)



[Belgium](#)



[Brazil](#)



[Canada](#)



[Croatia](#)



[Finland](#)



[France](#)



[Germany](#)



[Italy](#)



[Japan](#)



[Netherlands](#)



[Spain](#)



[Taiwan](#)

Project Jurisdictions

The process of developing licenses and discussing them are still in progress for the following jurisdictions:



[Argentina](#)



[Bulgaria](#)



[Chile](#)



[China](#)



[Ireland](#)



[Israel](#)



[Jordan](#)



[Poland](#)



[South Africa](#)



[South Korea](#)



[Sweden](#)



[Switzerland](#)



[United Kingdom](#)

Advanced Web Search

You can use the options on this page to create a very specific search. Just fill in the fields you need for your current search.

Yahoo! Search

Show results with	all of these words	<input type="text"/>	any part of the page <input type="button" value="v"/>
	the exact phrase	<input type="text"/>	any part of the page <input type="button" value="v"/>
	any of these words	<input type="text"/>	any part of the page <input type="button" value="v"/>
	none of these words	<input type="text"/>	any part of the page <input type="button" value="v"/>

Tip: Use these options to look for an exact phrase or to exclude pages containing certain words. You can also limit your search to certain parts of pages.

Updated

Site/Domain

- Any domain
- Only .com domains Only .edu domains
- Only .gov domains Only .org domains

only search in this domain/site:

Tip: You can search for results in a specific website (e.g. yahoo.com) or top-level domains (e.g. .com, .org, .gov).

Creative Commons Search **BETA**


Search only for **Creative Commons** licensed content

- Find content I can use for commercial purposes
- Find content I can modify, adapt, or build upon




Tip: This special Yahoo! Search finds pages that have content with a Creative Commons license. [Learn more...](#)


Backlinks to creativecommons.org via Yahoo! and All The Web



Standardizing: One philosophy, free legal tools to implement



Extended to science:



Brazil License



Generic License



Australian License





Thanks to MIT, CSAIL, the
Omidyar Network & the High
Q Foundation



HIGH Q FOUNDATION

ABOUT HIGH Q FOUNDATION, CHDI AND MRSSI

The **High Q Foundation, Inc.** is a private philanthropic foundation that was established in 2002 with the mission of bringing together academia, industry, governmental agencies, and other funding organizations in the search for **Huntington's disease (HD)** treatments. The Foundation supports numerous projects related to HD, including basic research, a drug-discovery program, and clinical studies.



Contact Info

Science Commons

32 Vassar Street

Building 32-386

Cambridge, MA 02139

Attention: MIT-CSAIL

Phone: 617-938-3475

<http://sciencecommons.org>

wilbanks@creativecommons.org